Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Differentiation-inducing factor-1 (**DIF-1**) is a small molecule polyketide originally identified in the slime mold *Dictyostelium discoideum* as a morphogen that induces prestalk cell differentiation[3][5][6]. In mammalian cells, especially various cancer cell lines, DIF-1 is known to exert **anti-proliferative effects** by multiple mechanisms: it induces cell cycle arrest at G1, suppresses the expression of cyclin D1, inhibits phosphorylation and activity of cyclin-dependent kinases (Cdk4, Cdk6, Cdk2), reduces levels of signal transducer and activator of transcription 3 (STAT3) via inhibition of translation, and downregulates activity of ribosomal protein S6 kinase (p70S6K/p85S6K)[1][2]. DIF-1 can also promote differentiation in vascular smooth muscle cells and upregulate specific smooth muscle markers[2]. In rodent models, intragastric administration of DIF-1 reduces tumor growth without noticeable adverse effects[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on differentiation-inducing factor-1.